- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Lipitor may be the first statin to switch to OTC
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Roxane Labs' generic prostate drug gets tentative approval from FDA
HAYWARD, Calif. — In response to articles that appeared in several media outlets about its generic drug pipeline, drug maker Impax Labs is looking to set the record straight.
The company said several financial websites had reported that Impax had found a way to make a generic version of Pfizer’s cholesterol-lowering drug Lipitor (atorvastatin calcium).
The company said that while it had 98 generic drugs in its development pipeline and had filed for approval for 36 drugs with the Food and Drug Administration, it had not filed an application for a generic version of Lipitor and did not have an agreement with any company to produce it.